

Title (en)  
HIGHLY ATTENUATED POX VIRUS STRAINS, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS PARAMUNITY INDUCERS OR FOR PRODUCING VECTOR VACCINES

Title (de)  
HOCHATTENUIERTE POXVIRUSSTÄMME, VERFAHREN ZUR IHRER HERSTELLUNG UND DEREN VERWENDUNG ALS PARAMUNITÄTSINDUCER ODER ZUR HERSTELLUNG VON VEKTOR-VAKZINEN

Title (fr)  
SOUCHES DE POXVIRUS FORTEMENT ATTENUÉES, PROCÉDE POUR LES PRODUIRE ET LEUR UTILISATION POUR INDUIRE LA PARAMUNITÉ, OU POUR PRÉPARER DES VACCINS À VECTEUR

Publication  
**EP 1893223 A1 20080305 (DE)**

Application  
**EP 06754393 A 20060616**

Priority  
• EP 2006005781 W 20060616  
• DE 102005027956 A 20050616

Abstract (en)  
[origin: CA2610277A1] The present invention relates to highly attenuated animal smallpox viral strains and to the use thereof as paramunity inducers or for producing vector vaccines. As a result of the high attenuation process, the claimed animal smallpox strains lose their virulent and immunising properties. The invention also relates to a method for producing such highly attenuated pox virus strains and the use thereof for inducing paramunity, i.e. for activating the non-specific immune system in mammals and humans or for producing vector vaccines for specific immunisation with the positive side-effect of paramunisation. The claimed highly attenuated animal smallpox viruses are thus suitable for preventing and treating diseases associated with an immune deficiency. Preferred embodiments relate to highly attenuated orthopox- (e.g. camel smallpox viruses), leporipox- (e.g. myxoma viruses), avipox-, parapox- and other orthopox viral strains, such as MVA, which have excellent paramunisation properties and in which the immunising properties have been lost.

IPC 8 full level  
**A61K 35/76** (2006.01); **A61K 39/39** (2006.01); **C12N 7/08** (2006.01)

CPC (source: EP US)  
**A61P 1/16** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 31/00** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 31/12** (2017.12 - EP); **A61P 31/16** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/04** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **C12N 7/00** (2013.01 - EP US); **A61K 35/13** (2013.01 - EP US); **A61K 2039/5252** (2013.01 - EP US); **A61K 2039/5254** (2013.01 - EP US); **C12N 2710/24064** (2013.01 - EP US)

Citation (search report)  
See references of WO 2006133947A1

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)  
**DE 102005027956 A1 20061221**; **DE 102005027956 B4 20091022**; AU 2006257065 A1 20061221; BR PI0611979 A2 20101013; CA 2610277 A1 20061221; CN 101198339 A 20080611; EP 1893223 A1 20080305; JP 2008546377 A 20081225; MX 2007016004 A 20080307; RU 2008101659 A 20090727; US 2008305129 A1 20081211; WO 2006133947 A1 20061221; ZA 200710562 B 20090325

DOCDB simple family (application)  
**DE 102005027956 A 20050616**; AU 2006257065 A 20060616; BR PI0611979 A 20060616; CA 2610277 A 20060616; CN 200680021399 A 20060616; EP 06754393 A 20060616; EP 2006005781 W 20060616; JP 2008516238 A 20060616; MX 2007016004 A 20060616; RU 2008101659 A 20060616; US 91731906 A 20060616; ZA 200710562 A 20071204